Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody

Huang, Kuo Chan; Wu, Herren

doi:10.1128/microbiolspec.aid-0014-2014

Cited by 8 publications

(6 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32,33 Most of the statistically significant correlations among respiratory viruses were positive associations, which could result from several factors, including shared transmission routes, interactions with the host immune system, or environmental conditions that favor multiple virus types. 34,35 It is also conceivable that variations across years in the drivers of transmission common to several viruses, such as unusual climate conditions, social contact patterns, or changes in healthcare-seeking behavior, could cause multiple viruses' incidences to deviate similarly from their expected seasonal periodicity. This synchronized deviation might have contributed to the observed positive correlations among virus pairs.…”

Section: Discussionmentioning

confidence: 99%

Interactions among acute respiratory viruses in Beijing, Chongqing, Guangzhou, and Shanghai, China, 2009–2019

Madewell,

Wang,

Dean

et al. 2023

Influenza Resp Viruses

View full text Add to dashboard Cite

BackgroundA viral infection can modify the risk to subsequent viral infections via cross‐protective immunity, increased immunopathology, or disease‐driven behavioral change. There is limited understanding of virus–virus interactions due to lack of long‐term population‐level data.MethodsOur study leverages passive surveillance data of 10 human acute respiratory viruses from Beijing, Chongqing, Guangzhou, and Shanghai collected during 2009 to 2019: influenza A and B viruses; respiratory syncytial virus A and B; human parainfluenza virus (HPIV), adenovirus, metapneumovirus (HMPV), coronavirus, bocavirus (HBoV), and rhinovirus (HRV). We used a multivariate Bayesian hierarchical model to evaluate correlations in monthly prevalence of test‐positive samples between virus pairs, adjusting for potential confounders.ResultsOf 101,643 lab‐tested patients, 33,650 tested positive for any acute respiratory virus, and 4,113 were co‐infected with multiple viruses. After adjusting for intrinsic seasonality, long‐term trends and multiple comparisons, Bayesian multivariate modeling found positive correlations for HPIV/HRV in all cities and for HBoV/HRV and HBoV/HMPV in three cities. Models restricted to children further revealed statistically significant associations for another ten pairs in three of the four cities. In contrast, no consistent correlation across cities was found among adults. Most virus–virus interactions exhibited substantial spatial heterogeneity.ConclusionsThere was strong evidence for interactions among common respiratory viruses in highly populated urban settings. Consistent positive interactions across multiple cities were observed in viruses known to typically infect children. Future intervention programs such as development of combination vaccines may consider spatially consistent virus–virus interactions for more effective control.

show abstract

Section: Discussionmentioning

confidence: 99%

Interactions among acute respiratory viruses in Beijing, Chongqing, Guangzhou, and Shanghai, China, 2009–2019

Madewell,

Wang,

Dean

et al. 2023

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…Palivizumab, RSV F proteininin A antijenik bölümündeki bir epitopa yönelik olarak rekombinan DNA teknolojisiyle üretilmiş hümanize bir IgG1 monoklonal antikordur. Virüsün, solunum epitel hücrelerine yapışmasını önleyerek RSV replikasyonunu azaltmaktadır (39). Yüksek riskli hastalarda RSV'ye bağlı ciddi alt solunum yolu enfeksiyonlarını engellemede onaylanmış tek immunoprofilaksi tedavisidir.…”

Section: öNleme Ve Immunoprofilaksiunclassified

Respiratory syncytial virüs infections in neonates and infants

Perk

Özdil

2018

Turk Pediatri Ars

View full text Add to dashboard Cite

Respiratory syncytial virus is one of the major causes of respiratory tract infections during infancy with high rates of hospitalization and mortality during the first years of life. It is the most common cause of acute bronchiolitis and viral pneumonia in children below two years of age and second the most common cause of postneonatal infant mortality all around the world following malaria. In addition, the virus has been causally linked to recurrent wheezing and associated with pediatric asthma. The respiratory syncytial virus infections tend to be severe in high risk patients such as patients below six months of age, with prematurity, congenital heart diseases, neuromuscular diseases and immune deficiencies. No specific treatment is available for respiratory syncytial virus infections to date. Severe cases require supportive therapy, mainly oxygen supplementation and hydration, and less frequently, ventilatory support. Because there is no vaccine to prevent respiratory syncytial virus infections or clinically effective treatment to administer to children with respiratory syncytial virus infection, immunoprophylaxis with palivizumab is currently the only method for reducing morbidity associated with severe respiratory syncytial virus in high-risk infants.

show abstract

“…21,22,25 No vaccines against hRSV have been approved. [25][26][27][28] Furthermore, only a single prophylactic antibody product, palivizumab, is licensed in a limited selection of cases. 17,29,30 In this sense, in most cases of hRSV infection, the primary management strategies are prevention, symptomatic management, and supportive therapy.…”

Section: Introductionmentioning

confidence: 99%

New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus

Diethelm‐Varela¹,

Soto²,

Riedel³

et al. 2023

IDR

View full text Add to dashboard Cite

Since the discovery of the human respiratory syncytial virus (hRSV), multiple research efforts have been conducted to develop vaccines and treatments capable of reducing the risk of severe disease, hospitalization, long-term sequelae, and death from this pathogen in susceptible populations. In this sense, therapies specifically directed against hRSV are mainly based on monoclonal and polyclonal antibodies such as intravenous IgG (IVIG)-RSV and the monoclonal antibody palivizumab. However, these therapies are associated with significant limitations, including the need for the recruitment of a high number of convalescent volunteers who donate blood to procure IVIG-RSV and the costs associated with the need for repeated administrations of palivizumab. These limitations render this product not cost-effective for populations other than high-risk patients. These problems have underscored that it is still necessary to identify new safe and effective therapies for human use. However, these new therapies must benefit from a comparatively cheap production cost and the opportunity to be available to the high-risk population and anyone who requires treatment. Here, we review the different antibodies used to prevent the pathology caused by hRSV infection, highlighting therapies currently approved for human use and their clinical value. Also, the new, most promising candidates based on preclinical studies and clinical trial results are revised.

show abstract

Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody

Cited by 8 publications

References 97 publications

Interactions among acute respiratory viruses in Beijing, Chongqing, Guangzhou, and Shanghai, China, 2009–2019

Interactions among acute respiratory viruses in Beijing, Chongqing, Guangzhou, and Shanghai, China, 2009–2019

Respiratory syncytial virüs infections in neonates and infants

New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus

Contact Info

Product

Resources

About